These studies with other literature [82,83,84,85,86] support the concept that the diagnostic criteria using biomarkers such as FeNO and IgE could be a landmark in facilitating a secure identification of ICS-responders among COPD patients. This evidence concerns the gene IGHE and chronic obstructive pulmonary disease.